Polyquaternium-1–Preserved Travoprost 0.003% or Benzalkonium Chloride–Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension
Purpose To demonstrate equivalence of polyquaternium-1–preserved travoprost 0.003% with benzalkonium chloride–preserved travoprost 0.004% in patients with open-angle glaucoma or ocular hypertension. Design Double-masked, randomized, 2-treatment, equivalence clinical trial. Methods setting…